My Cancer Genome: Genetically Informed Cancer Medicine

  • Home
  • DIRECT
  • About Us
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Anaplastic Large Cell Lymphoma
  • Basal Cell Carcinoma
  • Bladder Cancer
  • Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
  • Colorectal Cancer
  • GIST
  • Gastric Cancer
  • Glioma
  • Inflammatory Myofibroblastic Tumor
  • Lung Cancer
  • Medulloblastoma
  • Melanoma
  • Myelodysplastic Syndromes
  • Neuroblastoma
  • Ovarian Cancer
  • Prostate Cancer
  • Rhabdomyosarcoma
  • Thymic Carcinoma
  • Thyroid Cancer
  • Molecular Medicine
    • Anticancer Agents
    • Circulating Tumor DNA
    • Detecting Gene Alterations in Cancers
    • Immunotherapy in Cancer
    • Overview of Targeted Therapies for Cancer
    • Pathways
    • Types of Molecular Tumor Testing
  • Take Our Survey
  • Glossary
  • News
  • Our Team
  • Acknowledgements

RNA Splicing

The process of eukaryotic RNA splicing involves the excision of non-coding introns and the preservation and joining of coding exons in an RNA molecule (Figure 1). This process is achieved via the use of a spliceosome. RNA splicing is activated by the binding of the spliceosome to the RNA molecule. Many eukaryotic transcripts are alternatively spliced (Figure 2). In this process, a different subset of exons are joined together to create a new transcript. Exon skipping can also result from mutations that alter the genetically encoded splice site. Alternative splicing is a key mechanism for diversification of the transcriptome and proteome of most eukaryotic species, allowing for the generation of many alternate transcripts and protein products from a single gene.

splice color

Figure 1. RNA splicing is the process whereby non-coding introns are removed to create a sequence of coding exons. The splicing process is mediated by the spliceosome. The spliceosome is a complex of several RNA protein molecules including but not limited to ZRSR2, SRSF2, SF3B1, and U2AF1. Broadly, the spliceosome removes intronic sequences to generate the mRNA which will be used to translate the resultant protein. Specific nodes in the pathway that are therapeutically actionable are noted. Click here to open a larger version of this image in a new window.

 

alternative splicing

Figure 2. Alternative splicing is the process whereby non-coding introns and some exons are removed to create a sequence of coding exons. The resultant mRNA is an alternative transcript and may or may not be translated. If translated, an alternate protein product will be generated. Click here to open a larger version of this image in a new window.

Diseases in Which Pathway is Aberrantly Activated

  • Myelodysplastic syndromes

Genes Involved in the Pathway

  • SF3B1
  • SRSF2
  • U2AF1
  • ZRSR2

Last Updated: August 1, 2016

Disclaimer: The information presented at MyCancerGenome.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.

  • MCG Home |
  • About Us |
  • Acknowledgments |
  • Give |
  • Site Map |
  • Legal |
  • APIs and Licensing
My Cancer Genome is managed by the Vanderbilt-Ingram Cancer Center   Copyright © 2010 - 2017 MY CANCER GENOME